Discovery and Structure-Activity Relationship Studies of Novel Adenosine A1 Receptor-Selective Agonists

J Med Chem. 2022 Nov 10;65(21):14864-14890. doi: 10.1021/acs.jmedchem.2c01414. Epub 2022 Oct 21.

Abstract

A series of benzyloxy and phenoxy derivatives of the adenosine receptor agonists N6-cyclopentyl adenosine (CPA) and N6-cyclopentyl 5'-N-ethylcarboxamidoadenosine (CP-NECA) were synthesized, and their potency and selectivity were assessed. We observed that the most potent were the compounds with a halogen in the meta position on the aromatic ring of the benzyloxy- or phenoxycyclopentyl substituent. In general, the NECA-based compounds displayed greater A1R selectivity than the adenosine-based compounds, with N6-2-(3-bromobenzyloxy)cyclopentyl-NECA and N6-2-(3-methoxyphenoxy)cyclopentyl-NECA showing ∼1500-fold improved A1R selectivity compared to NECA. In addition, we quantified the compounds' affinity and kinetics of binding at both human and rat A1R using a NanoBRET binding assay and found that the halogen substituent in the benzyloxy- or phenoxycyclopentyl moiety seems to confer high affinity for the A1R. Molecular modeling studies suggested a hydrophobic subpocket as contributing to the A1R selectivity displayed. We believe that the identified selective potent A1R agonists are valuable tool compounds for adenosine receptor research.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / chemistry
  • Adenosine-5'-(N-ethylcarboxamide)
  • Animals
  • Halogens
  • Humans
  • Purinergic P1 Receptor Agonists*
  • Rats
  • Receptors, Purinergic P1*
  • Structure-Activity Relationship

Substances

  • Adenosine
  • Adenosine-5'-(N-ethylcarboxamide)
  • Halogens
  • Purinergic P1 Receptor Agonists
  • Receptors, Purinergic P1
  • N(6)-cyclopentyl 5'-N-ethylcarboxamidoadenosine